$5.8 Billion, page-20

"Can i ask what good interim results are we looking for that will give the FDA reasons for stopping the trial earlier"

Confirmation Phase 2 trial results would be enough IMO:

"All of the HF-MACE seen over 36 months in the Phase 2 trial occurred in control patients................with an overall 71% HF-MACE rate over 36 months. In contrast, no HF-MACE were seen over the entire 36 months in 150 million MPC-treated patients...........p=0.0007 "

Interesting to note that SI has stated (in one of the videos) that a the phase 2 group follow up showed this trend continuing hence the alteration of the primary end points.


my emphases